SLC25A1 and cancer: In the present study we further validated the induction of D-2-HG by SLC25A1 inhibition in additional cancer cell lines by applying genetic inhibition using RNAi technology and a novel, 3rd generation small molecule inhibitor of SLC25A1, CTPI2 [17].